Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and b...

Full description

Bibliographic Details
Main Authors:	Fortner, RT, Sarink, D, Schock, H, Johnson, T, Tjønneland, A, Olsen, A, Overvad, K, Affret, A, His, M, Boutron-Ruault, MC, Boeing, H, Trichopoulou, A, Naska, A, Orfanos, P, Palli, D, Sieri, S, Mattiello, A, Tumino, R, Ricceri, F, Bueno-de-Mesquita, HB, Peeters, PH, Van Gils, CH, Weiderpass, E, Lund, E, Quirós, JR, Agudo, A, Sánchez, MJ, Chirlaque, MD, Ardanaz, E, Dorronsoro, M, Key, T, Khaw, KT, Rinaldi, S, Dossus, L, Gunter, M, Merritt, MA, Riboli, E, Kaaks, R
Format:	Journal article
Language:	English
Published:	BioMed Central 2017

Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

Similar Items